ICON plc’s Post

I highly recommend this webinar. Dr. Voloshko and Dr. Callahan are very knowledgeable!

Cardiac safety testing is an important part of the approval of new chemical entities (NCEs). During the last 20 years cardiac safety testing has been focused on QT interval assessment as a surrogate for the potential of an NCE to cause “Torsade de Pointes” - a specific life-threatening ventricular arrhythmia that is potentially associated with QT interval prolongation. However, these analyses have been conducted using limited, short-term data in a resting state. Newer technologies allow for the collection of long-term data in a more dynamic, real-world setting. Join ICON’s cardiac safety experts Dr. Polina Voloshko and Dr. Timothy Callahan who will discuss how long-term cardiovascular data can support a cardiac safety portfolio, exploring new cardiac monitoring technologies and their applications, and methods of data collection and analysis. Register here: https://ow.ly/tLHH50Tghyn

Cardiac safety testing is an important part of the approval of new chemical entities (NCEs). During the last 20 years cardiac safety testing has been focused on QT interval assessment as a surrogate for the potential of an NCE to cause “Torsade de Pointes” - a specific life-threatening ventricular arrhythmia that is potentially associated with QT interval prolongation. However, these analyses have been conducted using limited, short-term data in a resting state. Newer technologies allow for the collection of long-term data in a more dynamic, real-world setting. Join ICON’s cardiac safety experts Dr. Polina Voloshko and Dr. Timothy Callahan who will discuss how long-term cardiovascular data can support a cardiac safety portfolio, exploring new cardiac monitoring technologies and their applications, and methods of data collection and analysis. Register here: https://ow.ly/tLHH50Tghyn

Cardiac safety testing is an important part of the approval of new chemical entities (NCEs). During the last 20 years cardiac safety testing has been focused on QT interval assessment as a surrogate for the potential of an NCE to cause “Torsade de Pointes” - a specific life-threatening ventricular arrhythmia that is potentially associated with QT interval prolongation. However, these analyses have been conducted using limited, short-term data in a resting state. Newer technologies allow for the collection of long-term data in a more dynamic, real-world setting. Join ICON’s cardiac safety experts Dr. Polina Voloshko and Dr. Timothy Callahan who will discuss how long-term cardiovascular data can support a cardiac safety portfolio, exploring new cardiac monitoring technologies and their applications, and methods of data collection and analysis. Register here: https://ow.ly/tLHH50Tghyn

🚨 Explore this clinical consensus paper on cardiac emergiencies in women, co-authored by our group leader Sigrun Halvorsen ✅ Despite equal treatment recommendations, women often receive less evidence-based care than men. ✅ Conditions like spontaneous coronary dissection, takotsubo cardiomyopathy, and peripartum cardiomyopathy demand specialized diagnosis and management. Gain valuable insights on improving cardiac emergency management for women and discover the gaps in evidence. 📖 Read the full paper here: https://lnkd.in/ePDSnx2p Oslo University Hospital Universitetet i Oslo Oslo Center for Clinical Heart Research European Heart Journal European Society of Cardiology #CardiacHealth #WomensHealth #ClinicalInsights #MedicalResearch #GenderEquity #kvinnehelse #Cardiology

Case Study: Incredible Heart We’re thrilled to showcase how Incredible Heart joined forces with NuvoAir Medical to infuse their cardiology practice with innovative, patient-focused care. Utilizing our cutting-edge solutions, Dr. Kunal Gurav and his team successfully streamlined operations, elevated patient outcomes, and engaged with patients in unprecedented ways. This partnership exemplifies the transformative role of technology in advancing cardiology care and crafting personalized care for every patient. Key Outcomes: - Start-up time reduced from 6 months to 6 weeks - Monthly operating costs cut by 70% - Revenue projections increased by 150% - 200+ patients in under 2 months 🔗 Read the full case study to see the results: https://hubs.li/Q02SX1Yv0

Cardiovascular care has the potential to be transformed by innovation! In a recent article authored by Bernardo Perez Villa, MD, MSc, Senior Engagement Partner, Innovations, Florida Market, highlights three technologies in development with Cleveland Clinic Innovations that are poised to reshape how we address cardiovascular diseases. “It is vital to keep up with cutting-edge developments in the dynamic field of cardiovascular medicine, and many startups armed with pre-market technologies are ready to transform cardiovascular healthcare,” shared Dr. Perez-Villa. “Here, we present three promising technologies that may reshape how we address cardiovascular diseases.” Cleveland Clinic Innovations portfolio companies Advanced NanoTherapies, Inc, Cardionomic Inc., and Mitria Medical, are featured. These innovations represent a significant leap forward in cardiovascular medicine, promising to improve patient care and outcomes. 💓 https://hubs.li/Q02Mc8nN0 #CardiovascularCare #MedicalInnovation #HealthcareTechnology #PatientOutcomes #ClevelandClinic

📢 New Publication Alert! The HESI Cardiac Safety Committee is excited to share our latest publication: "Detection of Contractility Changes in the Heart from Arterial Blood Pressure Data Using Symmetric Projection Attractor Reconstruction" in Frontiers in Physiology. This innovative study addresses a critical challenge in cardiovascular safety assessment—detecting drug-induced changes in cardiac contractility. Traditionally, left ventricular pressure (LVP) measurements, which are invasive and resource-intensive, have been the gold standard. However, this study introduces a novel method using Symmetric Projection Attractor Reconstruction (SPAR) to analyze arterial blood pressure (BP) signals as a non-invasive surrogate for LVP. 🔗 Link to the full publication here: https://lnkd.in/gqhz4kvi This work underscores our commitment to developing cutting-edge methods for improving cardiovascular safety in drug development and clinical practice. #CardiacSafety #HESI #Innovation

Can someone please explain why we all are the same human beings except few differences in our anatomy and genes, why IVUS use for optimal PCI is class I indication in European guidelines, while it is still a 2b in our USA clinical practice guidelines? Is the PCI procedures and procedural outcomes without IVUS or IVOCT guidance are much superior or equal to EU imaging guided PCI outcomes? We always lag behind same for TAVR, why? How many more imaging studies or whatelse are we waiting for for us to move the imaging guided PCI as Class I in our guidelines? "The American College of Cardiology/American Heart Association Guidelines assigned a Class IIb recommendation for IVUS or OCT, whereas the European Society of Cardiology Guidelines upgraded it to the Class I recommendation. In light of the fact that the present pooled analysis provided convincing evidence on the benefit of IVUS in patients undergoing complex PCI, it is plausible that these data could serve as an impetus for changing clinical practice and upgrading IVUS to the Class I recommendation". God knows?

#DidYouKnow? October 1903: The Birth of Electrocardiography In October 1903, Dutch physiologist Willem Einthoven forever changed the field of medicine with his pioneering invention of the electrocardiograph (#ECG). This breakthrough marked the beginning of modern cardiology and paved the way for the development of non-invasive diagnostic techniques that would become critical in monitoring and diagnosing heart conditions. Before Einthoven’s invention, physicians had limited tools to assess heart function. Although earlier attempts were made to measure the heart’s electrical activity, none were as precise or practical. Einthoven’s solution was his groundbreaking string galvanometer, a device that was much more sensitive than anything before it. It was capable of detecting the faint electrical currents generated by the heart, converting them into visible tracings that doctors could interpret. By meticulously recording these signals, Einthoven was able to identify and classify the different phases of the cardiac cycle, such as the P, Q, R, S, and T waves, which we still recognize on ECGs today. This innovation was the first step in developing modern diagnostic tools for heart diseases, such as arrhythmias, myocardial infarctions, and various forms of cardiac dysfunction. Thanks to Einthoven’s work, medical professionals could now diagnose heart issues that were previously hidden, providing new hope for millions of patients around the world. Willem Einthoven’s contributions did not go unrecognized. In 1924, he was awarded the #NobelPrize in Physiology or Medicine for his discovery of the mechanism of the electrocardiogram, solidifying his legacy as the father of electrocardiography. Although the technology has evolved over the past century, the fundamental principles established by Einthoven remain the foundation of all modern ECG machines. His work continues to save lives to this day. So, next time you see an ECG monitor, remember that it all started in October 1903, with Willem Einthoven’s string galvanometer and a revolutionary vision for cardiac care. #Cardiology #CardiacCare #CytoSorbents #HealthcareHistory #OctoberInHistory